Research and development - Press Releases

Date	Title	Company
04-May-2023	Alfa Chemistry’s Journey at Pittcon 2023 and ACS Spring 2023 Has Come to a Fruitful and Joyful End	Alfa Chemistry
02-May-2023	Filing of Form S-4 and Mailing of Definitive Proxy Statement by Rosecliff Acquisition Corp. I	Spectral MD Holdings, Ltd
02-May-2023	CPHI & PMEC China 2023 to see surge from pent up international ingredients demand	CPHI
02-May-2023	Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis	Almirall
02-May-2023	Tay Therapeutics Announces Licensing to VYNE Therapeutics of Oral BET Inhibitor for immuno-inflammatory and fibrotic disorders	Tay Therapeutics
02-May-2023	Calibre Scientific Completes the Acquisition of Eppendorf’s Micro Manipulation Product Portfolio and Assumes Control of Sales and Service Operations	Calibre Scientific
02-May-2023	Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure	Sequana Medical
28-Apr-2023	Discovery Park appoints entrepreneur and bio-business leader as Head of Innovation	Discovery Park
27-Apr-2023	Alfa Chemistry Expresses Gratitude to Everyone Who Visited Its Booth at the ACS Spring 2023 Conference	Alfa Chemistry
27-Apr-2023	CD Formulation Unveils Its Latest Offering: A Comprehensive Line of Pharmaceutical Formulation Characterization Testing Services	CD Formulation
26-Apr-2023	ValiRx and Physiomics join forces to provide seamless data integration	ValiRx
25-Apr-2023	Introducing the Copley Impactor Genie™ IG 200i, a two-in-one solution for quicker, more efficient inhaled product testing	Copley Scientific
25-Apr-2023	Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies	Vedanta Biosciences
25-Apr-2023	Parkinson's device company secures strategic investment from Crimson International Investment	PD Neurotechnology
25-Apr-2023	Alchemab Therapeutics to present data profiling a novel antibody to Huntingtin Exon 1 at the CHDI Annual Huntington’s Disease Therapeutics Conference	Alchemab Therapeutics
25-Apr-2023	CARMAT obtains non-dilutive financing of €13.2 million within the framework of the “France 2030” plan	CARMAT
25-Apr-2023	CD Formulation Enhances Its Food Ingredients Lineup with Upgraded Acidity Regulators, Anticaking Agents, and Coating Agents	CD Formulation
25-Apr-2023	Alfa Chemistry Newly Introduces Three APIs to Meet Market Demands: Tofacitinib Citrate, Tamoxifen Citrate, and Epalrestat	Alfa Chemistry
25-Apr-2023	ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board	ImmunOs Therapeutics
24-Apr-2023	Pioneering cancer treatment that can increase remissions by two years approved on the NHS	Myeloma UK